CalciMedica Announces Clinical Development of Auxora May Proceed Following FDA Review of KOURAGE Trial Interim Safety Data
Rhea-AI Summary
CalciMedica (Nasdaq: CALC) reported that the FDA has reviewed a protocol amendment and interim safety data from the Phase 2 KOURAGE trial of Auxora in Stage 2/3 AKI with AHRF and provided no comments, allowing dosing to continue.
An Independent Data Monitoring Committee had previously prompted a pause in enrollment due to a mortality imbalance, though no drug-related toxicity was identified. A safety review of 107 dosed patients found serious adverse events consistent with prior Auxora experience. CalciMedica also anticipates FDA feedback in Q3 2026 on a potential pivotal Auxora program in acute pancreatitis.
Positive
- FDA completed review of KOURAGE protocol amendment and interim safety data with no comments
- KOURAGE trial may continue dosing Auxora in Stage 2/3 AKI with AHRF
- Safety assessment of 107 patients found SAEs consistent with prior Auxora experience
- Company expects FDA feedback in Q3 2026 on potential pivotal acute pancreatitis program
Negative
- Previous KOURAGE enrollment pause due to IDMC-identified mortality imbalance
- Protocol design required revisions for baseline disease severity imbalances
- Enrollment pause likely delays overall KOURAGE trial timelines
News Market Reaction – CALC
In the Jun 24 session, CALC declined 25.64%, reflecting a significant negative market reaction. Argus tracked a peak move of +53.4% during that session. Argus tracked a trough of -38.1% from its starting point during tracking. Our momentum scanner triggered 52 alerts that day, indicating high trading interest and price volatility. Trading volume was exceptionally heavy at 173.5x the daily average, suggesting significant selling pressure.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Clinical trial Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jan 28 | Trial discontinued | Negative | -75.6% | Discontinuation of Phase 2 KOURAGE AKI trial after IDMC safety concern. |
| Jun 25 | Design publication | Positive | -4.8% | KOURAGE design and rationale published with promising preclinical and CARDEA data. |
| Jul 09 | First patient dosed | Positive | +4.5% | First patient enrolled in Phase 2 KOURAGE AKI trial with AHRF endpoints. |
| Jun 27 | Positive CARPO data | Positive | -32.4% | Positive topline Phase 2b CARPO data in acute pancreatitis including safety profile. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Clinical-trial headlines for CALC have produced volatile and mixed reactions, with an average move of -27.09% and both strong rallies and sharp selloffs.
Key Terms
acute kidney injury medical
acute hypoxemic respiratory failure medical
independent data monitoring committee clinical
serious adverse events medical
clinical hold regulatory
ind amendment regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
FDA reviewed a protocol amendment and interim safety data from the KOURAGE trial evaluating Auxora in AKI patients
No comments or questions were received
Confirms CalciMedica's ability to continue clinical development of Auxora across indications
In January 2026, CalciMedica announced a pause in enrollment for the Phase 2 KOURAGE trial following a recommendation from the trial's Independent Data Monitoring Committee (IDMC) regarding a safety concern relating to a mortality imbalance that warranted reevaluation of the study design. The IDMC did not identify evidence of drug-related toxicity, and the Company's comprehensive review, performed in conjunction with external experts, reached the same conclusion while identifying imbalances in patients' baseline disease severity that necessitated revisions to the protocol design.
In March 2026, CalciMedica submitted an amendment to the KOURAGE trial to address design issues, which included refinements to patient inclusion criteria and changes to stratification methodology. The submission included a comprehensive safety assessment of the 107 patients who were dosed prior to the pause in enrollment, including cause-of-death information for all deaths and an analysis of serious adverse events (SAEs). Based on the Company's review, the observed SAEs were consistent with previous clinical experience with Auxora and did not appear to be drug related. The FDA has confirmed that the Clinical Pharmacology team of the Division of Cardiology and Nephrology has no comments regarding this submission. As the KOURAGE trial was never placed on clinical hold, and the decision to pause enrollment was made solely at the discretion of the Company, the FDA is not obligated to respond to the IND amendment. Following more than 60 days of review, the information contained in the amendment has resulted in no comments or questions from the FDA and no clinical hold communication.
CalciMedica expects feedback from the FDA on the design of a potential pivotal program evaluating Auxora in acute pancreatitis in the third quarter of 2026.
About CalciMedica
CalciMedica is a clinical-stage biopharmaceutical company developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for inflammatory, immunologic, and cardiopulmonary diseases. The Company's pipeline includes Auxora™ (zegocractin), its intravenous CRAC channel inhibitor, and CM5480, its proprietary, selective oral CRAC channel inhibitor candidate. Auxora has been evaluated in more than 350 patients across completed and ongoing clinical trials and is planned to be evaluated in a Phase 1b proof-of-concept study in patients with pulmonary arterial hypertension (PAH). CM5480 is being developed as a potential chronic oral therapy for chronic inflammatory diseases such as pulmonary hypertension (PH), with IND clearance expected in mid-2027. Together, the programs are intended to establish CRAC channel inhibition as a differentiated therapeutic approach targeting both pulmonary vascular remodeling and right ventricular dysfunction in PH. For more information, please visit www.calcimedica.com.
Forward-Looking Statements
This communication contains forward-looking statements which include, but are not limited to, statements regarding CalciMedica's clinical development plans for Auxora™, including in acute kidney injury and acute pancreatitis; CalciMedica's ability to continue dosing patients with Auxora in the KOURAGE trial or otherwise continue clinical development of Auxora following FDA review of the KOURAGE protocol amendment and interim safety data; CalciMedica's interpretation of the FDA's lack of comments or questions regarding the submission; the potential resumption, continuation, design, conduct, timing, enrollment or completion of the KOURAGE trial or any future clinical trial evaluating Auxora in AKI; the potential safety, efficacy, clinical utility and regulatory development path for Auxora; CalciMedica's expectation to receive feedback from FDA regarding the design of a potential pivotal program evaluating Auxora in acute pancreatitis in the third quarter of 2026; CalciMedica's plans to advance CM5480 as a potential oral therapy for PH; and the potential of CalciMedica's proprietary technology to provide therapeutic benefits in inflammatory, immunologic and cardiopulmonary diseases. These forward-looking statements are subject to the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. CalciMedica's expectations and beliefs regarding these matters may not materialize. Actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of uncertainties, risks, and changes in circumstances, including but not limited to risks and uncertainties related to: the impact of fluctuations in global financial markets on CalciMedica's business and the actions it may take in response thereto; CalciMedica's ability to execute its plans and strategies; the ability to obtain and maintain regulatory approval for Auxora and CM5480; results from clinical trials or preclinical studies may not be indicative of results that may be observed in the future; potential safety and other complications from Auxora and CM5480; the scope, progress and expansion of developing and commercializing Auxora; the size and growth of the market therefor and the rate and degree of market acceptance thereof; economic, business, competitive, and/or regulatory factors affecting the business of CalciMedica generally; CalciMedica's ability to protect its intellectual property position; the impact of government laws and regulations; and CalciMedica's financial position and need for additional capital. Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included under the caption "Risk Factors" in CalciMedica's Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, filed with the SEC on May 12, 2026, and elsewhere in CalciMedica's subsequent reports on Form 10-K, Form 10-Q or Form 8-K filed with the SEC from time to time and available at www.sec.gov. These documents can be accessed on CalciMedica's web page at ir.calcimedica.com/financials-filings/sec-filings. The forward-looking statements contained herein are made as of the date hereof, and CalciMedica undertakes no obligation to update them after this date, except as required by law.
Contact Information
Kevin Murphy
calcimedica@argotpartners.com
(212) 600-1902
View original content to download multimedia:https://www.prnewswire.com/news-releases/calcimedica-announces-clinical-development-of-auxora-may-proceed-following-fda-review-of-kourage-trial-interim-safety-data-302808584.html
SOURCE CalciMedica, Inc.